Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica - Sweden
doi 10.2340/00015555-2748
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Acta Dermato-Venereologica

Related search

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

820 M6A mRNA Demethylase FTO Regulates Tumorigenicity and Response to Anti-Pd-1 Immunotherapy in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Gut Microbiome Affects the Response to Anti-Pd-1 Immunotherapy in Patients With Hepatocellular Carcinoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

Beyond PD-1 Immunotherapy in Malignant Melanoma

Dermatology and Therapy
Dermatology
2019English

Circulating Tumor DNA to Monitor Treatment Response and Detect Acquired Resistance in Patients With Metastatic Melanoma

Oncotarget
Oncology
2015English

Circulating Tumor DNA as an Early Indicator of Response to T-Cell Transfer Immunotherapy in Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

Utility of Circulating B-Raf DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy